This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Zosano Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$13.53m
Eşitlik	US$14.05m
Toplam yükümlülükler	US$12.39m
Toplam varlıklar	US$26.45m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0ZP's short term assets ($15.6M) exceed its short term liabilities ($9.7M).

Uzun Vadeli Yükümlülükler: 0ZP's short term assets ($15.6M) exceed its long term liabilities ($2.7M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0ZP is debt free.

Borcun Azaltılması: 0ZP has no debt compared to 5 years ago when its debt to equity ratio was 39.1%.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0ZP has less than a year of cash runway based on its current free cash flow.

Tahmini Nakit Akışı: 0ZP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.4% each year

This company is no longer active

Zosano Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

First quarter 2022 earnings released: US$7.87 loss per share (vs US$2.73 loss in 1Q 2021)

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Revenue in line with expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: €1.26

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

New 90-day high: €0.90

New 90-day high: €0.64

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

New 90-day low: €0.21

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

New 90-day low: €0.54

New 90-day low: €0.64

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - €1.11

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin